[go: up one dir, main page]

GT201300229A - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents

Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Info

Publication number
GT201300229A
GT201300229A GT201300229A GT201300229A GT201300229A GT 201300229 A GT201300229 A GT 201300229A GT 201300229 A GT201300229 A GT 201300229A GT 201300229 A GT201300229 A GT 201300229A GT 201300229 A GT201300229 A GT 201300229A
Authority
GT
Guatemala
Prior art keywords
tfpi
monoclonal antibodies
inhibitor
antibodies against
route
Prior art date
Application number
GT201300229A
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Marquardt Tobias
Moosmayer Dieter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300229(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300229A publication Critical patent/GT201300229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONAN ANTICUERPOS MONOCLONALES AISLADOS QUE SE UNEN A EPÍTOPOS ESPECÍFICOS DEL INHIBIDOR DE LA RUTA DEL FACTOR TISULAR HUMANO (TFPI) Y LAS MOLÉCULAS DE ÁCIDO NUCLEICO AISLADAS QUE LOS CODIFICAN. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS ANTICUERPOS MONOCLONALES ANTI-TFPI Y PROCEDIMIENTOS DE TRATAMIENTO DE DEFICIENCIAS O DEFECTOS EN LA COAGULACIÓN POR LA ADMINISTRACIÓN DE LOS ANTICUERPOS.
GT201300229A 2011-04-01 2013-09-27 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) GT201300229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
GT201300229A true GT201300229A (es) 2014-11-13

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300229A GT201300229A (es) 2011-04-01 2013-09-27 Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Country Status (37)

Country Link
US (5) US20140294832A1 (es)
EP (1) EP2694544B1 (es)
JP (4) JP6170903B2 (es)
KR (2) KR101995302B1 (es)
CN (2) CN103797030B (es)
AU (3) AU2012236296A1 (es)
BR (1) BR112013025376A2 (es)
CA (2) CA3068997A1 (es)
CL (1) CL2013002811A1 (es)
CO (1) CO6890074A2 (es)
CR (1) CR20130499A (es)
CU (1) CU20130128A7 (es)
CY (1) CY1121538T1 (es)
DK (1) DK2694544T3 (es)
DO (1) DOP2013000218A (es)
EA (2) EA201991704A3 (es)
EC (1) ECSP13012913A (es)
ES (1) ES2722824T3 (es)
GT (1) GT201300229A (es)
HK (1) HK1243426A1 (es)
HR (1) HRP20190467T1 (es)
HU (1) HUE042706T2 (es)
IL (4) IL228633B (es)
LT (1) LT2694544T (es)
MX (1) MX2013011218A (es)
MY (2) MY165499A (es)
PE (1) PE20141149A1 (es)
PH (4) PH12013502039B1 (es)
PL (1) PL2694544T3 (es)
PT (1) PT2694544T (es)
RS (1) RS58633B1 (es)
SG (2) SG10201602606UA (es)
SI (1) SI2694544T1 (es)
TR (1) TR201905101T4 (es)
UA (1) UA113623C2 (es)
WO (1) WO2012135671A2 (es)
ZA (1) ZA201308169B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379096B1 (en) 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
PT2379600E (pt) 2008-12-22 2014-04-29 Novo Nordisk As Anticorpos contra inibidor da via de fator tecidual
PL2542257T3 (pl) 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
WO2012135671A2 (en) * 2011-04-01 2012-10-04 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ724133A (en) * 2012-03-21 2020-07-31 Baxalta Inc Tfpi inhibitors and methods of use
MX2014011781A (es) * 2012-03-30 2014-11-26 Bayer Healthcare Llc Anticuerpos regulados por proteasa.
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2970497B1 (en) 2013-03-15 2017-10-25 Bayer HealthCare LLC Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
WO2014140240A1 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
JP6584397B2 (ja) * 2013-07-19 2019-10-02 ノヴォ ノルディスク アー／エス 凝血促進活性を誘発することができる組織因子経路インヒビターのｎ末端部分を認識する抗体
EP3194447B1 (en) * 2014-09-17 2021-12-01 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
MX388251B (es) * 2015-02-25 2025-03-19 Mogam Inst Biomedical Res Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
KR102438650B1 (ko) * 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
US20210263052A1 (en) * 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
PT2379600E (pt) * 2008-12-22 2014-04-29 Novo Nordisk As Anticorpos contra inibidor da via de fator tecidual
PL2542257T3 (pl) * 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
WO2012135671A2 (en) * 2011-04-01 2012-10-04 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
US20170107298A1 (en) 2017-04-20
SG193594A1 (en) 2013-10-30
PH12013502039A1 (en) 2013-12-16
KR101995302B1 (ko) 2019-07-02
MX2013011218A (es) 2013-10-17
AU2012236296A1 (en) 2013-10-24
PT2694544T (pt) 2019-04-02
CO6890074A2 (es) 2014-03-10
ECSP13012913A (es) 2014-02-28
US20220041752A1 (en) 2022-02-10
LT2694544T (lt) 2019-04-25
EP2694544A4 (en) 2015-03-25
EA201991704A2 (ru) 2020-03-31
CA2831907C (en) 2020-03-24
SI2694544T1 (sl) 2019-06-28
CN107090046A (zh) 2017-08-25
WO2012135671A2 (en) 2012-10-04
PE20141149A1 (es) 2014-08-28
JP6363747B2 (ja) 2018-07-25
MY165499A (en) 2018-03-27
AU2017203105A1 (en) 2017-06-01
PL2694544T3 (pl) 2019-07-31
JP2018172411A (ja) 2018-11-08
WO2012135671A3 (en) 2012-12-13
TR201905101T4 (tr) 2019-05-21
ES2722824T3 (es) 2019-08-19
KR20190079698A (ko) 2019-07-05
CY1121538T1 (el) 2020-05-29
IL257145A (en) 2018-03-29
PH12019500439A1 (en) 2020-10-12
PH12013502039B1 (en) 2013-12-16
IL274686A (en) 2020-06-30
CL2013002811A1 (es) 2014-02-28
AU2019201814A1 (en) 2019-04-04
EP2694544B1 (en) 2019-01-23
KR20140019428A (ko) 2014-02-14
US20180194857A1 (en) 2018-07-12
PH12019500441A1 (en) 2020-10-12
DK2694544T3 (en) 2019-04-15
UA113623C2 (uk) 2017-02-27
JP2017113019A (ja) 2017-06-29
EA201301107A1 (ru) 2014-11-28
ZA201308169B (en) 2016-03-30
NZ615969A (en) 2016-01-29
IL228633B (en) 2018-03-29
IL228633A0 (en) 2013-12-31
SG10201602606UA (en) 2016-04-28
EP2694544A2 (en) 2014-02-12
IL283829A (en) 2021-07-29
RS58633B1 (sr) 2019-05-31
EA201991704A3 (ru) 2020-06-30
CA2831907A1 (en) 2012-10-04
HUE042706T2 (hu) 2019-07-29
DOP2013000218A (es) 2013-11-15
US20140294832A1 (en) 2014-10-02
HRP20190467T1 (hr) 2019-05-03
HK1243426A1 (zh) 2018-07-13
CU20130128A7 (es) 2014-03-26
US20190194353A1 (en) 2019-06-27
CN103797030B (zh) 2017-05-31
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
CA3068997A1 (en) 2012-10-04
EA034214B1 (ru) 2020-01-17
IL274686B (en) 2021-09-30
CN103797030A (zh) 2014-05-14
CR20130499A (es) 2013-10-24
JP2021019619A (ja) 2021-02-18
BR112013025376A2 (pt) 2017-07-25
JP6170903B2 (ja) 2017-07-26
JP2014511685A (ja) 2014-05-19

Similar Documents

Publication Publication Date Title
GT201300229A (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
DOP2012000239A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
CU23880B1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121736T1 (el) Άλατα aramchol
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
BR112018010933A2 (pt) anticorpos multiespecíficos
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
CY1120132T1 (el) Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
BR112013020913A2 (pt) tratamento de doença de crohn fistulizante
DOP2012000266A (es) PROTEÍNAS QUE SE UNEN AL TNF-a
BR112013017080A2 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
PL413202A1 (pl) Sposób pozyskiwania helenaliny i dihydrohelenaliny oraz estrów tych substancji z kultur in vitro Arnica i ich zastosowanie
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv